Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Anokion

    - PMLiVE

    Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

    Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

    The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront

    The candidate has shown potential in treating B-cell mediated autoimmune diseases

    - PMLiVE

    AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn

    The companies are aiming to develop MGDs for targets across oncology and immunology

    - PMLiVE

    AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

    The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

    - PMLiVE

    Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

    The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

    - PMLiVE

    GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m

    The company plans to develop the candidate for autoimmune diseases such as lupus

    - PMLiVE

    GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

    The companies aim to develop a portfolio of up to ten candidates

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links